The DOI matches its Crossref record; 101 of the 101 references it cites were found in a registry or an index.
Metronomic chemotherapy: new rationale for new directions
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
Tumor angiogenesis: therapeutic implications
Sherwood, L. M., Parris, E. E., & Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197111182852108 · Cited by 10,187
Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., & Thun, M. J. (2009) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20006 · Cited by 9,709
Cancer immunoediting: from immunosurveillance to tumor escape
Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., & Schreiber, R. D. (2002) · Nature Immunology · doi:10.1038/ni1102-991 · Cited by 5,393
Tumorigenesis and the angiogenic switch
Bergers, G., & Benjamin, L. E. (2003) · Nature reviews. Cancer · doi:10.1038/nrc1093 · Cited by 3,559
Modes of resistance to anti-angiogenic therapy
Bergers, G., & Hanahan, D. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2442 · Cited by 2,953 · cited 1×
“Nevertheless, both intrinsic and acquired resistance to anti-angiogenic drugs are emerging as clinically relevant issues”
BackgroundTransplacental Carcinogenesis by Stilbestrol
Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197108122850711 · Cited by 2,640
Pàez-Ribes, M., Allen, E., Hudock, J., Takeda, T., Okuyama, H., Viñals, F., Inoue, M., Bergers, G., Hanahan, D., & Casanovas, O. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.01.027 · Cited by 2,339
Kerbel, R. S. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0706596 · Cited by 1,948
Immunological aspects of cancer chemotherapy
Zitvogel, L., Apetoh, L., Ghiringhelli, F., & Kroemer, G. (2008) · Nature Reviews Immunology · doi:10.1038/nri2216 · Cited by 1,712
Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis
Ebos, J. M. L., Lee, C. R., Cruz-Munoz, W., Bjarnason, G. A., Christensen, J. G., & Kerbel, R. S. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.01.021 · Cited by 1,709
Cancer as an evolutionary and ecological process
Merlo, L. M. F., Pepper, J. W., Reid, B. J., & Maley, C. C. (2006) · Nature Reviews Cancer · doi:10.1038/nrc2013 · Cited by 1,699
Models, mechanisms and clinical evidence for cancer dormancy
Aguirre-Ghiso, J. A. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2256 · Cited by 1,677
Tumor heterogeneity: Causes and consequences
Marusyk, A., & Polyak, K. (2010) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2009.11.002 · Cited by 1,602
Browder, T. D., Butterfield, C., Kräling, B. M., Shi, B., Marshall, B., OʼReilly, M., & Folkman, J. (2000) · PubMed · Cited by 1,543
The anti-angiogenic basis of metronomic chemotherapy
Kerbel, R. S., & Kamen, B. A. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1369 · Cited by 1,397
Ghiringhelli, F., Menard, C., Puig, P. E., Ladoire, S., Roux, S., Martin, F., Solary, E., Le Cesne, A., Zitvogel, L., & Chauffert, B. (2007) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-006-0225-8 · Cited by 1,241
Klement, G., Baruchel, S., Rak, J., Man, S., Clark, K., Hicklin, D. J., Bohlen, P., & Kerbel, R. S. (2000) · Journal of Clinical Investigation · doi:10.1172/jci8829 · Cited by 1,168
Circulating Tumor Cells in Patients with Breast Cancer Dormancy
Meng, S., Tripathy, D., Frenkel, E. P., Shete, S., Naftalis, E. Z., Huth, J. F., Beitsch, P. D., Leitch, M., Hoover, S., Euhus, D., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1110 · Cited by 971
Lutsiak, M. E. C., Semnani, R. T., De Pascalis, R., Kashmiri, S. V. S., Schlom, J., & Sabzevari, H. (2005) · Blood · doi:10.1182/blood-2004-06-2410 · Cited by 903
TUMOR DORMANCY IN VIVO BY PREVENTION OF NEOVASCULARIZATION
Gimbrone, M. A., Leapman, S. B., Cotran, R. S., & Folkman, J. (1972) · The Journal of Experimental Medicine · doi:10.1084/jem.136.2.261 · Cited by 903
Ghiringhelli, F., Larmonier, N., Schmitt, E., Parcellier, A., Cathelin, D., Garrido, C., Chauffert, B., Solary, E., Bonnotte, B., & Martin, F. (2004) · European Journal of Immunology · doi:10.1002/eji.200324181 · Cited by 880
Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice
Hanahan, D., Bergers, G., & Bergsland, E. (2000) · Journal of Clinical Investigation · doi:10.1172/jci9872 · Cited by 865
Gatenby, R. A., Silva, A. S., Gillies, R. J., & Frieden, B. R. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3658 · Cited by 846
A Randomized Trial of Adjuvant Chemotherapy with Uracil–Tegafur for Adenocarcinoma of the Lung
Kato, H., Ichinose, Y., Ohta, M., Hata, E., Tsubota, N., Tada, H., Watanabe, Y., Wada, H., Tsuboi, M., Hamajima, N., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032792 · Cited by 818
(2003) · PubMed · Cited by 608
Kavallaris, M., Kuo, D. Y., Burkhart, C. A., Regl, D. L., Norris, M. D., Haber, M., & Horwitz, S. B. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119642 · Cited by 601
Self-citationBiomarkers of response and resistance to antiangiogenic therapy
Jain, R. K., Duda, D. G., Willett, C. G., Sahani, D. V., Zhu, A. X., Loeffler, J. S., Batchelor, T. T., & Sorensen, A. G. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.63 · Cited by 572
A New Description of Cellular Quiescence
Coller, H. A., Sang, L., & Roberts, J. M. (2006) · PLoS Biology · doi:10.1371/journal.pbio.0040083 · Cited by 555
Garcia, A. A., Hirte, H., Fleming, G., Yang, D., Tsao-Wei, D. D., Roman, L., Groshen, S., Swenson, S., Markland, F., Gandara, D., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.1939 · Cited by 547
Multidrug Resistance: Retrospect and Prospects in Anti-Cancer Drug Treatment
Perez-Tomas, R. (2006) · Current Medicinal Chemistry · doi:10.2174/092986706777585077 · Cited by 509
Colleoni, M., Rocca, A., Sandri, M. T., Zorzino, L., Masci, G., Nolè, F., Peruzzotti, G., Robertson, C., Orlando, L., Cinieri, S., et al. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf013 · Cited by 496
Bocci, G., Nicolaou, K. C., & Kerbel, R. S. (2002) · PubMed · Cited by 444
Kerbel, R. S. (1991) · BioEssays · doi:10.1002/bies.950130106 · Cited by 441
Redefining the Target: Chemotherapeutics as Antiangiogenics
Miller, K. D., Sweeney, C. J., & Sledge, G. W. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.4.1195 · Cited by 395
Silencing or Fueling Metastasis with VEGF Inhibitors: Antiangiogenesis Revisited
Loges, S., Mazzone, M., Hohensinner, P., & Carmeliet, P. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.02.007 · Cited by 393
Zetterberg, A., & Larsson, O. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.16.5365 · Cited by 372
Lymphoma-Specific Genetic Aberrations in Microvascular Endothelial Cells in B-Cell Lymphomas
Streubel, B., Chott, A., Huber, D., Exner, M., Jäger, U., Wagner, O., & Schwarzinger, I. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033153 · Cited by 318
Man, S., Bocci, G., Francia, G., Green, S. K., Jothy, S., Hanahan, D., Böhlen, P., Hicklin, D. J., Bergers, G., & Kerbel, R. S. (2002) · PubMed · Cited by 314
Metronomic Cyclophosphamide and Capecitabine Combined With Bevacizumab in Advanced Breast Cancer
Dellapasqua, S., Bertolini, F., Bagnardi, V., Campagnoli, E., Scarano, E., Torrisi, R., Shaked, Y., Mancuso, P., Goldhirsch, A., Rocca, A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.4789 · Cited by 293
Kono, K., Kawaida, H., Takahashi, A., Sugai, H., Mimura, K., Miyagawa, N., Omata, H., & Fujii, H. (2006) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-005-0092-8 · Cited by 288
Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model
Banissi, C., Ghiringhelli, F., Chen, L., & Carpentier, A. F. (2009) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-009-0671-1 · Cited by 255
Mancuso, P., Colleoni, M., Calleri, A., Orlando, L., Maisonneuve, P., Pruneri, G., Agliano, A., Goldhirsch, A., Shaked, Y., Kerbel, R. S., et al. (2006) · Blood · doi:10.1182/blood-2005-11-4570 · Cited by 252
Metronomic scheduling: the future of chemotherapy?
Gasparini, G. (2001) · The Lancet Oncology · doi:10.1016/s1470-2045(01)00587-3 · Cited by 251
Klement, G. L., Huang, P. H., Mayer, B., Green, S. K., Man, S., Böhlen, P., Hicklin, D. J., & Kerbel, R. S. (2002) · PubMed · Cited by 243
Xiong, Y.-Q., Sun, H.-C., Zhang, W., Zhu, X.-D., Zhuang, P.-Y., Zhang, J.-B., Wang, L., Wu, W.-Z., Qin, L.-X., & Tang, Z.-Y. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2780 · Cited by 214
Reardon, D. A., Desjardins, A., Vredenburgh, J. J., Gururangan, S., Sampson, J. H., Sathornsumetee, S., McLendon, R. E., Herndon, J. E., Marcello, J. E., Norfleet, J., et al. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605412 · Cited by 206
Kieran, M. W., Turner, C. D., Rubin, J. B., Chi, S. N., Zimmerman, M. A., Chordas, C., Klement, G., Laforme, A., Gordon, A., Thomas, A., et al. (2005) · Journal of Pediatric Hematology/Oncology · doi:10.1097/01.mph.0000183863.10792.d4 · Cited by 199
Bottini, A., Generali, D., Brizzi, M. P., Fox, S. B., Bersiga, A., Bonardi, S., Allevi, G., Aguggini, S., Bodini, G., Milani, M., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.5773 · Cited by 189
Colleoni, M., Orlando, L., Sanna, G., Rocca, A., Maisonneuve, P., Peruzzotti, G., Ghisini, R., Sandri, M. T., Zorzino, L., Nolè, F., et al. (2006) · Annals of Oncology · doi:10.1093/annonc/mdj066 · Cited by 186
Prolonged tumor dormancy by prevention of neovascularization in the vitreous.
Brem, S. S., Brem, H., Folkman, J., Finkelstein, D., & Patz, A. (1976) · PubMed · Cited by 178
Tanaka, H., Matsushima, H., Mizumoto, N., & Takashima, A. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1101 · Cited by 163
Metronomic therapy with cyclophosphamide and dexamethasone for prostate carcinoma
Glode, L. M., Barqawi, A., Crighton, F., Crawford, E. D., & Kerbel, R. (2003) · Cancer · doi:10.1002/cncr.11713 · Cited by 162
Generali, D., Bates, G., Berruti, A., Brizzi, M. P., Campo, L., Bonardi, S., Bersiga, A., Allevi, G., Milani, M., Aguggini, S., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1507 · Cited by 160
du Manoir, J. M., Francia, G., Man, S., Mossoba, M. E., Medin, J. A., Viloria‐Petit, A., Hicklin, D. J., Emmenegger, U., & Kerbel, R. S. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1109 · Cited by 151
Pasquier, E., André, N., & Braguer, D. (2007) · Current Cancer Drug Targets · doi:10.2174/156800907781662266 · Cited by 149
Self-citationVOGT, T. M., Hafner, C. M., Bross, K., Bataille, F., Jauch, K., Berand, A., Landthaler, M., Andreesen, R., & Reichle, A. (2003) · Cancer · doi:10.1002/cncr.11775 · Cited by 146
Tanaka, H., Matsushima, H., Nishibu, A., Clausen, B. E., & Takashima, A. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1106 · Cited by 134
Cellular senescence: Its role in tumor suppression and aging
Ohtani, N., Mann, D. J., & Hara, E. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01123.x · Cited by 134
Understanding tumor endothelial cell abnormalities to develop ideal anti‐angiogenic therapies
Hida, K., Hida, Y., & Shindoh, M. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2007.00704.x · Cited by 129
Temozolomide rechallenge in recurrent malignant glioma by using a continuous temozolomide schedule
Perry, J., Rizek, P., Cashman, R. L., Morrison, M., & Morrison, T. (2008) · Cancer · doi:10.1002/cncr.23813 · Cited by 122
Chuu, C., Hiipakka, R. A., Fukuchi, J., Kokontis, J. M., & Liao, S. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3992 · Cited by 121
Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults
Kesari, S., Schiff, D., Doherty, L. M., Gigas, D. C., Batchelor, T. T., Muzikansky, A., O’Neill, A., Drappatz, J., Chen‐Plotkin, A. S., Ramakrishna, N. R., et al. (2007) · Neuro-Oncology · doi:10.1215/15228517-2007-006 · Cited by 121
Taxol-dependent mutants of Chinese hamster ovary cells with alterations in alpha- and beta-tubulin.
Schibler, M. J., & Cabral, F. (1986) · The Journal of Cell Biology · doi:10.1083/jcb.102.4.1522 · Cited by 120
Orlando, L., Cardillo, A., Ghisini, R., Rocca, A., Balduzzi, A., Torrisi, R., Peruzzotti, G., Goldhirsch, A., Pietri, E., & Colleoni, M. A. (2006) · BMC Cancer · doi:10.1186/1471-2407-6-225 · Cited by 119
Neoplastic circulating endothelial cells in multiple myeloma with 13q14 deletion
Rigolin, G. M., Fraulini, C., Ciccone, M., Mauro, E., Bugli, A. M., Angeli, C. D., Negrini, M., Cuneo, A., & Castoldi, G. (2005) · Blood · doi:10.1182/blood-2005-04-1768 · Cited by 112
Low Dose Metronomic Oral Cyclophosphamide for Hormone Resistant Prostate Cancer: A Phase II Study
Lord, R., Nair, S., Schache, A. G., Spicer, J. F., Somaihah, N., Khoo, V. S., & Pandha, H. (2007) · The Journal of Urology · doi:10.1016/j.juro.2007.01.143 · Cited by 110
Buckstein, R. J., Kerbel, R. S., Shaked, Y., Nayar, R., Foden, C., Turner, R. A., Lee, C. R., Taylor, D., Zhang, L., Man, S., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0474 · Cited by 110
Dose-Ranging Study of Metronomic Oral Vinorelbine in Patients with Advanced Refractory Cancer
Briasoulis, E. C., Pappas, P., Puozzo, C., Tolis, C., Fountzilas, G., Dafni, U. G., Μαρσέλος, Μ., & Pavlidis, N. A. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0970 · Cited by 104
Vascular Remodeling Marks Tumors That Recur During Chronic Suppression of Angiogenesis
Huang, J., Soffer, S. Z., Kim, E. S., McCrudden, K. W., Huang, J. T., New, T. N., Manley, C. A., Middlesworth, W., O’Toole, K., Yamashiro, D. J., et al. (2004) · Molecular Cancer Research · doi:10.1158/1541-7786.36.2.1 · Cited by 101
Watanabe, T., Sano, M., Takashima, S., Kitaya, T., Tokuda, Y., Yoshimoto, M., Kohno, N., Nakagami, K., Iwata, H., Shimozuma, K., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.3939 · Cited by 97
Tumor dormancy of primary and secondary cancers
Udagawa, T. (2008) · Apmis · doi:10.1111/j.1600-0463.2008.01077.x · Cited by 94
Loeffler, M. W., Krüger, J. A., & Reisfeld, R. A. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0646 · Cited by 88
Stempak, D., Gammon, J., Halton, J., et al. (2006) · Journal of Pediatric Hematology/Oncology · doi:10.1097/01.mph.0000243657.64056.c3 · Cited by 88
Fontana, A., Galli, L., Fioravanti, A., Orlandi, P., Galli, C., Landi, L. M., Bursi, S., Allegrini, G., Fontana, E., Marsico, R. D., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-3317 · Cited by 88
Molecular and cellular biomarkers for angiogenesis in clinical oncology
Bertolini, F., Mancuso, P., Shaked, Y., & Kerbel, R. S. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2007.08.011 · Cited by 83
Wong, N. S., Buckman, R. A., Clemons, M. J., Verma, S., Dent, S. F., Trudeau, M., Roche, K., Ebos, J. M. L., Kerbel, R. S., DeBoer, G., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.0143 · Cited by 83
The significance of Treg cells in defective tumor immunity
Kosmaczewska, A., Ciszak, L., Potoczek, S., & Frydecka, I. (2008) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-008-0018-1 · Cited by 80
Štěrba, J., Valík, D., Múdry, P., Kepák, T., Pavelka, Z., Bajčiová, V., Zitterbart, K., Kadlecová, V., & Mazánek, P. (2006) · Oncology Research and Treatment · doi:10.1159/000093474 · Cited by 78
Maintenance of long‐term tumour‐specific T‐cell memory by residual dormant tumour cells
Mahnke, Y. D., Schwendemann, J., Beckhove, P., & Schirrmacher, V. (2005) · Immunology · doi:10.1111/j.1365-2567.2005.02163.x · Cited by 76
Bhatt, R. S., Merchan, J. R., Parker, R. A., Wu, H., Zhang, L., Seery, V. J., Heymach, J. V., Atkins, M. B., McDermott, D. F., & Sukhatme, V. P. (2010) · Cancer · doi:10.1002/cncr.24902 · Cited by 72
Cabral, F. R. (1983) · The Journal of Cell Biology · doi:10.1083/jcb.97.1.22 · Cited by 72
Oral low-dose cyclophosphamide in metastatic hormone refractory prostate cancer (MHRPC)
Nicolini, A., Pa, M., Ferrari, P., Anselmi, L., Tartarelli, G., Bonazzi, V., Carpi, A., & Giardino, R. (2004) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2004.08.006 · Cited by 72
Metronomic chemotherapy: an antiangiogenic scheduling
Laquente, B., Viñals, F., & Germà, J. R. (2007) · Clinical & Translational Oncology · doi:10.1007/s12094-007-0018-3 · Cited by 71
Kong, D., Lee, J.-I., Kim, W. K., Son, M. J., Lim, D. H., Kim, S. H., Park, K., Kim, J. W., Eoh, W., & Nam, D. (2006) · Oncology Reports · doi:10.3892/or.16.5.1117 · Cited by 70
Combined oral cyclophosphamide and bevacizumab in heavily pre-treated ovarian cancer
Jurado, J. M., Sánchez, A., Pajares, B., Pérez-Ruiz, E., Alonso, L., & Alba, E. (2008) · Clinical & Translational Oncology · doi:10.1007/s12094-008-0254-7 · Cited by 68
T-cell immunity in the induction and maintenance of a tumour dormant state
Schirrmacher, V. (2001) · Seminars in Cancer Biology · doi:10.1006/scbi.2001.0384 · Cited by 65
Brizzi, M. P., Berruti, A., Ferrero, A., Milanesi, E., Volante, M., Castiglione, F., Birocco, N., Bombaci, S., Perroni, D., Ferretti, B., et al. (2009) · BMC Cancer · doi:10.1186/1471-2407-9-388 · Cited by 64
A highly epothilone B–resistant A549 cell line with mutations in tubulin that confer drug dependence
Yang, C. H., Verdier‐Pinard, P., Wang, F., Lippaine-Horvath, E., He, L., Li, D., Höfle, G., Ojima, I., Orr, G. A., & Horwitz, S. B. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0024 · Cited by 63
Choi, L. M. R., Rood, B., Kamani, N. R., Lafond, D. A., Packer, R. J., Santi, M. R., & MacDonald, T. J. (2007) · Pediatric Blood & Cancer · doi:10.1002/pbc.21381 · Cited by 61
Systems Biology: A Therapeutic Target for Tumor Therapy
Reichle, A., & VOGT, T. M. (2008) · Cancer Microenvironment · doi:10.1007/s12307-008-0012-5 · Cited by 59
Intermittent androgen blockade should be regarded as standard therapy in prostate cancer
Šeruga, B., & Tannock, I. F. (2008) · Nature Clinical Practice Oncology · doi:10.1038/ncponc1180 · Cited by 57
Stopping Treatment Can Reverse Acquired Resistance to Letrozole
Sabnis, G. J., Macedo, L. F., Goloubeva, O. G., Schayowitz, A., & Brodie, A. M. H. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5999 · Cited by 56
Spieth, K., Kaufmann, R., & Gille, J. (2003) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-003-0678-9 · Cited by 55
Glioma-associated endothelial cells are chemoresistant to temozolomide
Virrey, J. J., Golden, E. B., Sivakumar, W., et al. (2009) · Journal of Neuro-Oncology · doi:10.1007/s11060-009-9891-7 · Cited by 49
The multiple personality disorder phenotype(s) of circulating endothelial cells in cancer
Bertolini, F., Mancuso, P., Braidotti, P., Shaked, Y., & Kerbel, R. S. (2009) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2009.04.003 · Cited by 41
de Weerdt, O. (2001) · The Netherlands Journal of Medicine · doi:10.1016/s0300-2977(01)00140-1 · Cited by 40
Krzyzanowska, M. K., Tannock, I. F., Lockwood, G. A., Knox, J. J., Moore, M. J., & Bjarnason, G. A. (2006) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-006-0347-x · Cited by 39
Oral metronomic cyclophosphamide in elderly with metastatic melanoma
Borne, E., Desmedt, E., Duhamel, A., Mirabel, X., Dziwniel, V., Maire, C., Florin, V., Martinot, V. L., Penel, N., Vercambre-Darras, S., et al. (2009) · Investigational New Drugs · doi:10.1007/s10637-009-9298-5 · Cited by 38
Herrlinger, U., Rieger, J., Steinbach, J. P., N�gele, T., DICHGANS, J., & Weller, M. (2005) · Journal of Neuro-Oncology · doi:10.1007/s11060-004-1726-y · Cited by 35
Antiangiogenic Metronomic Chemotherapy
Sarmiento, R., & Gasparini, G. (2008) · Onkologie · doi:10.1159/000119925 · Cited by 19
Cited by
Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors
Galluzzi, L., Humeau, J., Buqué, A., Zitvogel, L., & Kroemer, G. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0413-z · Cited by 1,349
Unifying niche shift studies: insights from biological invasions
Guisan, A., Petitpierre, B., Broennimann, O., Daehler, C., & Kueffer, C. (2014) · Trends in Ecology & Evolution · doi:10.1016/j.tree.2014.02.009 · Cited by 810
Tumor metastasis: moving new biological insights into the clinic
Wan, L., Pantel, K., & Kang, Y. (2013) · Nature Medicine · doi:10.1038/nm.3391 · Cited by 748
(2016) · ecancermedicalscience · doi:10.3332/ecancer.2014.463 · Cited by 676
The challenge of drug resistance in cancer treatment: a current overview
Nikolaou, M., Pavlopoulou, A., Georgakilas, A. G., & Kyrodimos, E. (2018) · Clinical & Experimental Metastasis · doi:10.1007/s10585-018-9903-0 · Cited by 600
Metadata
- Authors
- Pasquier, E., Kavallaris, M., & André, N.
- Venue
- Nature Reviews Clinical Oncology
- Published
- 2010-06-08
- Volume
- 7
- Issue
- 8
- Pages
- 455-465
- ISSN
- 1759-4774 (ISSN-L)
- 1759-4782
- OpenAlex
- W2090806526
- Cited by
- 659
- References
- 101
- FWCI
- 3.04
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.